Skip to main content
SpringerLink
Log in

Effect of dopamine agonist medication on prolactin producing pituitary adenomas

A morphological study including immunocytochemistry, electron microscopy and in situ hybridization

  • Published:
Virchows Archiv A Aims and scope Submit manuscript

Summary

Conventional light microscopy, immunocyto-chemistry, electron microscopy and in situ hybridization were used to evaluate the effect of dopamine agonists (bromocriptine-LAR and bromocriptine) on the morphology of surgically removed prolactin (PRL)-producing pituitary adenomas. Dopamine agonist therapy resulted in decrease of serum PRL, clinical improvement and tumour shrinkage. Using light and electron microscopy cellular atrophy, interstitial and perivascular fibrosis were noted; in several tumours connective tissue accumulation was pronounced. The cellular response was not uniform. In some adenomas populations of large cells and small cells were distinguished. The large cells contained immunoreactive PRL and expressed the PRL gene indicating resistance to dopamine agonists. It appears that these cells retained the potential to secrete PRL and proliferate despite exposure to dopamine agonists. In the small cells, PRL immunoreactivity and PRL gene expression decreased providing evidence that both PRL release and synthesis were blocked. Small cells can persist in tumours after discontinuation of dopamine agonist medication suggesting these small cells are irreversibly suppressed and are not capable of regaining their endocrine function and proliferative capability. The formation of irreversibly suppressed PRL cells may explain why some PRL-producing adenomas do not recur after withdrawal of dopamine agonists.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Asa SL, Gerry BM, Singer W, Horvath E, Kovacs K, Smyth HS (1986) Gonadotropin secretion in vitro by human pituitary null cell adenomas and oncocytomas. J Clin Endocrinol Metab 62:1011–1019

    Google Scholar 

  • Bannister P, Sheridan P (1987) Continued growth of a large pituitary prolactinoma despite high dose bromocriptine. Br J Clin Pract 41:712–713

    Google Scholar 

  • Barrow DL, Tindall GT, Kovacs K, Thorner MO, Horvath E, Hoffman JC Jr (1984) Clinical and pathological effects of bromocriptine on prolactin-secreting and other pituitary tumors. J Neurosurg 60:1–7

    Google Scholar 

  • Bassetti M, Spada A, Pezzo G, Giannattasio J (1984) Bromocriptine treatment reduces the cell size in human macroprolactinomas: a morphometric study. J Clin Endocrinol Metab 58:268–273

    Google Scholar 

  • Breidahl HD, Topliss DJ, Pike JW (1983) Failure of bromocriptine to maintain reduction in size of a macroprolactinoma. Br Med J 287:451–452

    Google Scholar 

  • Bression D, Brandi AM, Martres MP, Nousbarin A, Cesselin F, Peillon F (1980) Dopaminergic receptors in human prolactinsecreting adenomas: a quantitative study. J Clin Endocrinol Metab 51:1037–1043

    Google Scholar 

  • Cheyne KL, Lightner ES, Comerci GD (1988) Bromocriptine-unresponsive porlactin macroadenoma in a prepuberal female. J Adolesc Health Care 9:331–334

    Google Scholar 

  • Chiodini P, Luizzi A, Cozzi R, Verde G, Oppirri G, Dallabonzana O, Spella B, Silverstini P, Borghi G, Lucarelli G, Reiner E, Horonski R (1981) Size reduction of macroprolactinomas by bromocriptine or lisuride treatment. J Clin Endocrinol Metab 52:727–743

    Google Scholar 

  • Ciccarelli E, Ghigo E, Mazza E, Massara F, Lancranjan I, Camanni F (1987) Effects of a new long-acting form of bromocriptine on tumorours hyperprolactinemia. J Endocinrol Invest 10:179–182

    Google Scholar 

  • Corenblum B (1985) The medical treatment of the hypersecreting pituitary gland. Can J Neurol Sci 12:243–250

    Google Scholar 

  • Corenblum B, Hanley DA (1981) Bromocriptine reduction of prolactinoma size. Fertil Steril 36:716–719

    Google Scholar 

  • Corenblum B, Taylor PJ (1983) Long-term follow-up of hyperprolactinemic women treated with bromocriptine. Fertil Steril 40:596–599

    Google Scholar 

  • Cronin MJ (1982) The role and direct measurement of the dopamine receptor(s) in the anterior pituitary. Neuroendocrinol Perspect 1:169–210

    Google Scholar 

  • Esiri MM, Bevan JS, Burke CW, Adams CB (1986) Effect of bromocriptine treatment on the fibrous tissue content of prolactin-secreting and nonfunctioning macroadenomas of the pituitary gland. J Clin Endocrinol Metab 63:338–388

    Google Scholar 

  • Fahlbusch R, Buchfelder M, Schnell U (1987) Short-term preoperative treatment of macroprolactinomas by dopamine agonists. J Neurosurg 67:807–815

    Google Scholar 

  • Grossman A, Ross R, Was JAH, Besser GM (1986) Depot-bromocriptine treatment for prolactinomas and acromegaly. Clin Endocrinol 24:231–238

    Google Scholar 

  • Hassoun J, Jaquet P, Devictor B, Andonian C, Crisoli F, Gunoz G, Toga M (1985) Bromocriptine effects on cultured human prolactin-producing pituitary adenomas: in vitro ultrastructural, morphometric, and immunoelectron microscopic studies. J Clin Endocrinol Metab 61:686–692

    Google Scholar 

  • Horvath E, Kovacs K (1986) Pathology of prolactin cell adenomas of the human pituitary. Semin Diagn Pathol 3:4–17

    Google Scholar 

  • Horvath E, Kovacs K, Killinger DW, Gonzalez J, Smith HS (1988) Diverse ultrastructural response to dopamine agonist medication in human pituitary prolactin cell adenomas. In: Hoshino K (ed) Prolactin gene family and its receptors. Elsevier, Amsterdam, pp 307–311

    Google Scholar 

  • Johnston DG, Prescott RWG, Kendall-Taylor P, Hall K, Crombie AL, Hall R, McGregor A, Watson MJ, Cook DB (1983) Hyperprolactinemia. Long-term effects of bromocriptine. Am J Med 75:868–874

    Google Scholar 

  • Johnston DG, Hall K, Kendall-Taylor P, Patrick D, Watson M, Cook DR (1984) Effect of dopamine agonist withdrawal after long-term therapy in prolactinomas. Studies with high-definition computerized tomography. Lancet II:187–192

    Google Scholar 

  • Jordan RM, Kohler PO (1987) Recent advances in diagnosis and treatment of pituitary tumors. Adv Intern Med 32:299–323

    Google Scholar 

  • Koga M, Nakao H, Arao M, Sato B, Noma K, Morimoto Y, Kishimoto S, Mori S, Nozumi T (1987) Demonstration of specific dopamine receptors on human pituitary adenomas. Acta Endocrinol (Copenh) 114:595–602

    Google Scholar 

  • Kovacs K, Horvath E (1986) Tumors of the pituitary gland. Atlas of tumor pathology, fascicle XXI, 2nd series. Armed Forces Institute of Pathology, Washington, D.C., pp 96–115

    Google Scholar 

  • Kovacs K. Lloyd R, Horvath E, Asa SL, Stefaneanu L, Killinger DW, Smyth HS (1989) Silent somatotroph adenomas of the human pituitary. A morphologic study of three cases including immunocytochemistry, electron microscopy in vitro examination, and in situ hybridization. Am J Pathol 134:345–353

    Google Scholar 

  • Kupersmith MJ, Kleinburg D, Warren FA, Budzilovitch G, Cooper P (1989) Growth of prolactinoma despite lowering of serum prolactin by bromocriptine. Neurosurgery 24:417–423

    Google Scholar 

  • Landolt AM, Osterwalder V (1984) Perivascular fibrosis in prolactinoma: is it increased by bromocriptine. J Clin Endocrinol Metab 58:1179–1183

    Google Scholar 

  • Landolt AM, Osterwalder V, Landolt TA (1987) Storage and release of secretory granules in human prolactinomas: modification by bromocriptine. J Endocrinol 113:495–499

    Google Scholar 

  • Liuzzi A, Dallabonzana D, Oppizzi G, Verde GG, Gozzi R, Chiondini P, Luccarelli G (1985) Low doses of dopamine agonists in the long-term treatment of macroprolactinomas. N Engl J Med 313:656–659

    Google Scholar 

  • Maurer RA (1980) Dopaminergic inhibition of prolactin synthesis and prolactin messenger RNA accumulation in cultured pituitary cells. J Biol Chem 255:8092–8097

    Google Scholar 

  • McGregor AM, Scanlon MR, Hall R, Hall K (1979) Effects of bromocriptine on pituitary tumour size. Br Med J 2:700–703

    Google Scholar 

  • Molitch ME (1989) Management of prolactinomas. Annu Rev Med 40:255–232

    Google Scholar 

  • Molitch ME, Elton RL, Blackwell RE, Caldwell B, Chang RJ, Jaffe R, Joplin G, Robbins RJ, Tyson J, Thorner MO (1985) The bromocriptine study group. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab 60:698–705

    Google Scholar 

  • Montini M, Pagani G, Gianol D, Pagani MD, Sahnoraighi M, Ferrari L, Lancranjan I (1986) Long-lasting suppression of prolactin secretion and rapid shrinkage of prolactinomas after a long-acting injectable form of bromocriptine. J Clin Endocrinol Metab 63:266–268

    Google Scholar 

  • Moriondo P, Travaglini P, Nissinm M, Conti A, Faglia G (1985) Bromocriptine treatment of microprolactinoms: evidence of stable prolactin decrease after drug withdrawal. J Clin Endocrinol Metab 60:764–772

    Google Scholar 

  • Nabarro JDN (1982) Pituitary prolactinomas. Clin Endocrinol 17:129–155

    Google Scholar 

  • Nillius SJ, Bergh T, Lundberg PO, Stahle J, Wide L (1978) Regression of a prolactin-secreting pituitary tumor during long-term treatment with bromocriptine. Fertil Steril 30:710–712

    Google Scholar 

  • Rengachary SS, Tomita T, Jefferies BF, Watanabe I (1982) Structural changes in human pituitary tumor after bromocriptine therapy. Neurosurgery 10:242–251

    Google Scholar 

  • Saitoh Y, Mori S, Arita N, Hayakawa T, Mogani H, Matsumoto K, Mori H (1986) Cytosuppressive effect of bromocriptine on human prolactinomas: stereological analysis of ultrastructural alterations with special references to secretory granules. Cancer Res 46:1507–1512

    Google Scholar 

  • Schettini G, Lombardi G, Merola B, Miletto P, Fariello C, Cirillo S, Fusco R, Lancranjan I (1988) Effectiveness of a single injectable dose of bromocriptine long acting in the treatment of macroprolactinomas. J Endocrinol Invest 11:47–51

    Google Scholar 

  • Schottke H, Saeger W, Ludecke DK, Caselitz J (1986) Ultrastructural morphometry of prolactin secreting adenomas treated with dopamine agonists. Pathol Res Pract 181:280–290

    Google Scholar 

  • Thorner MO, Marin KH, Rogol AD, Morris JL, Perryman RL, Conway BP, Howards SS, Wolfman MG, MacLeod RM (1980) Rapid regression of pituitary prolactinomas during bromocriptine treatment. J Clin Endocrinol Metab 51:438–445

    Google Scholar 

  • Thorner MO, Perryman RL, Rogol AD, Gunay BP, MacLeod RM, Logan IS, Morris JL (1981) Rapid changes in prolactinoma volume following withdrawal and reinstitution of bromocriptine. J Clin Endocrinol Metab 53:480–483

    Google Scholar 

  • Tindall GT, Kovacs K, Horvath E, Thorner MO (1982) Human prolactin-producing adenomas and bromocriptine: a histological, immunocytochemical, ultrastructural and morphometric study. J Clin Endocrinol Metab 55:1178–1183

    Google Scholar 

  • Vance ML, Thorner MO (1987) Prolactinomas. Endocrinol Metab Clin North Am 16:731–753

    Google Scholar 

  • Wang CV, Lam KSL, Ma JTC, Chan T, Liu MY, Yeung RTT (1987) Long-term treatment of hyperprolactinaemia with bromocriptine: effect of drug withdrawal. Clin Endocrinol 27:363–371

    Google Scholar 

  • Verlant JW van't, Lancranjan I, Hendriks MJ, Croughs RJM (1988) Primary treatment of macroprolactinomas with Parlodel LAR. Acta Endocrinol (Copenh) 119:51–55

    Google Scholar 

  • Zarate A, Canales ES, Cano C, Philonieta CJ (1983) Follow-up of patients with prolactinomas after discontinuation of long-term therapy with bromocriptine. Acta Endocrinol (Copenh) 104:139–142

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada

    K. Kovacs, L. Stefaneanu & E. Horvath

  2. Department of Pathology, University of Michigan, Ann Arbor, Michigan, USA

    R. V. Lloyd

  3. Division of Neuroendocrinology, Sandoz Pharmaceutical, Basel, Switzerland

    I. Lancranjan

  4. Department of Neurosurgery, University of Erlangen-Nürnberg, Erlangen, Federal Republic of Germany

    M. Buchfelder & R. Fahlbusch

Authors
  1. K. Kovacs
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. Stefaneanu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Horvath
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. V. Lloyd
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. I. Lancranjan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Buchfelder
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R. Fahlbusch
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kovacs, K., Stefaneanu, L., Horvath, E. et al. Effect of dopamine agonist medication on prolactin producing pituitary adenomas. Vichows Archiv A Pathol Anat 418, 439–446 (1991). https://doi.org/10.1007/BF01605931

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01605931

Key words

Search

Navigation